Payment overview · 2025
General Payments
$780.80
31 reported records · 8 companies
Healthcare provider profile · identity verified
Ronald M. Eimen
Allopathic & Osteopathic Physicians|Family Medicine|Hospice and Palliative Medicine · MANNFORD, OK · NPI 1588756951
Verified facts
What the public records show
CMS Open Payments records show Ronald M. Eimen received $780.80 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Farxiga, Jardiance, Mounjaro, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $341.34 | 43.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.62 | 12.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.01 | 11.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $76.06 | 9.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.45 | 9.7% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.82 | 5.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.98 | 4.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.52 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.80 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $212.74 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.73 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.01 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $76.06 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.45 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $62.06 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 107 |
| Gabapentin | Gabapentin | 434 | 89 |
| Lisinopril | Lisinopril | 387 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 239 | 56 |
| Potassium Chloride | Potassium Chloride | 238 | 44 |
| Trazodone Hcl | Trazodone Hcl | 238 | 52 |
| Eliquis | Apixaban | 234 | 36 |
| Losartan Potassium | Losartan Potassium | 233 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 230 | 36 |
| Sertraline Hcl | Sertraline Hcl | 215 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 214 | 37 |
| Furosemide | Furosemide | 211 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 45 |
| Carvedilol | Carvedilol | 190 | 43 |
| Omeprazole | Omeprazole | 190 | 55 |
| Metformin Hcl | Metformin Hcl | 185 | 41 |
| Jardiance | Empagliflozin | 159 | 29 |
| Donepezil Hcl | Donepezil Hcl | 132 | 23 |
| Tramadol Hcl | Tramadol Hcl | 121 | 34 |
| Prednisone | Prednisone | 120 | 62 |
| Meloxicam | Meloxicam | 118 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 23 |
| Mounjaro | Tirzepatide | 114 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 40 |
| Montelukast Sodium | Montelukast Sodium | 111 | 31 |
| Finasteride | Finasteride | 110 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 21 |
| Xarelto | Rivaroxaban | 105 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 28 |
| Memantine Hcl | Memantine Hcl | 99 | 17 |
| Mirtazapine | Mirtazapine | 86 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 33 |
| Levetiracetam | Levetiracetam | 78 | suppressed |
| Baclofen | Baclofen | 75 | 14 |
| Ozempic | Semaglutide | 73 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 27 |
| Alendronate Sodium | Alendronate Sodium | 70 | 18 |
| Farxiga | Dapagliflozin Propanediol | 68 | 17 |
| Simvastatin | Simvastatin | 67 | 17 |
| Nystatin | Nystatin | 66 | 27 |
| Topiramate | Topiramate | 64 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 11 |
| Pregabalin | Pregabalin | 63 | 14 |
| Torsemide | Torsemide | 63 | 17 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Chlorthalidone | Chlorthalidone | 55 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 17 |
| Atenolol | Atenolol | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 15 |
| Prazosin Hcl | Prazosin Hcl | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 21 |
| Allopurinol | Allopurinol | 47 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 17 |
| Spironolactone | Spironolactone | 45 | 13 |
| Sucralfate | Sucralfate | 45 | 13 |
| Celecoxib | Celecoxib | 43 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Verapamil Er | Verapamil Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 30 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 38 |
| Azithromycin | Azithromycin | 39 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Metformin Hcl Er | Metformin Hcl | 32 | 12 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 29 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 15 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Nyamyc | Nystatin | 20 | 12 |
| Nystop | Nystatin | 20 | 12 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Armodafinil | Armodafinil | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Austedo Xr | Deutetrabenazine | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.80 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, Dexcom G6 Transmitter, FANAPT, FARXIGA, JARDIANCE, MOUNJARO, REXULTI, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error